Connect your AI

Repligen RGEN Gain (Loss), Foreign Currency Transaction, before Tax

Gain (Loss), Foreign Currency Transaction, before Tax at other companies

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

Revenue$194.3M+14.8%

Gross profit$108.3M+18.5%

Operating income$15.9M+142%

Net income$8.3M+42.9%

EPS (diluted)$0.15+50.0%

Balance sheet

Cash & equivalents$582.7M-16.4%

Total debt$687.6M+346%

Total equity$2.1B+6.0%

Total assets$2.9B+2.8%

Cash flow

Operating cash flow$28.3M+88.6%

CapEx$4.7M+32.2%

Free cash flow$23.6M+106%

Valuation

Market cap$7.45B-7.1%

Enterprise value$7.55B+2.1%

P/E144.9×—

P/S10.1×-0.1×

Profitability

Gross margin49.5%+2.7pp

Operating margin1.5%-14.0pp

Net margin17.1%-3.7pp

FCF margin21.2%+6.1pp

Returns & leverage

Return on equity2.5%+1.9pp

Debt / equity0.3×+0.2×

Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's gain (loss), foreign currency transaction, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Repligen's gain (loss), foreign currency transaction, before tax?: Repligen (RGEN) reported gain (loss), foreign currency transaction, before tax of -$38K in Q1 2026.
How has Repligen's gain (loss), foreign currency transaction, before tax changed year-over-year?: Repligen's gain (loss), foreign currency transaction, before tax decreased by 100.5% year-over-year, from $8.21M to -$38K.